ID   CLK4_HUMAN              Reviewed;         481 AA.
AC   Q9HAZ1;
DT   19-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   12-OCT-2022, entry version 168.
DE   RecName: Full=Dual specificity protein kinase CLK4;
DE            EC=2.7.12.1;
DE   AltName: Full=CDC-like kinase 4;
GN   Name=CLK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY,
RP   AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LYS-189.
RC   TISSUE=Kidney;
RX   PubMed=11170754; DOI=10.1006/geno.2000.6447;
RA   Schultz J., Jones T., Bork P., Sheer D., Blencke S., Steyrer S.,
RA   Wellbrock U., Bevec D., Ullrich A., Wallasch C.;
RT   "Molecular characterization of a cDNA encoding functional human CLK4 kinase
RT   and localization to chromosome 5q35.";
RL   Genomics 71:368-370(2001).
RN   [2]
RP   ERRATUM OF PUBMED:11170754.
RA   Schultz J., Jones T., Bork P., Sheer D., Blencke S., Steyrer S.,
RA   Wellbrock U., Bevec D., Ullrich A., Wallasch C.;
RL   Genomics 74:251-251(2001).
RN   [3]
RP   INTERACTION WITH UBL5.
RX   PubMed=12824502; DOI=10.1110/ps.0382803;
RA   McNally T., Huang Q., Janis R.S., Liu Z., Olejniczak E.T., Reilly R.M.;
RT   "Structural analysis of UBL5, a novel ubiquitin-like modifier.";
RL   Protein Sci. 12:1562-1566(2003).
RN   [4]
RP   INTERACTION WITH UBL5.
RX   PubMed=12705895; DOI=10.1016/s0006-291x(03)00549-7;
RA   Kantham L., Kerr-Bayles L., Godde N., Quick M., Webb R., Sunderland T.,
RA   Bond J., Walder K., Augert G., Collier G.;
RT   "Beacon interacts with cdc2/cdc28-like kinases.";
RL   Biochem. Biophys. Res. Commun. 304:125-129(2003).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-138, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-138, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-136 AND SER-138, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   FUNCTION, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=19168442; DOI=10.1161/circresaha.108.183905;
RA   Eisenreich A., Bogdanov V.Y., Zakrzewicz A., Pries A., Antoniak S.,
RA   Poller W., Schultheiss H.P., Rauch U.;
RT   "Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of
RT   tissue factor in human endothelial cells.";
RL   Circ. Res. 104:589-599(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-138, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-138, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-352 AND VAL-363.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual specificity kinase acting on both serine/threonine and
CC       tyrosine-containing substrates. Phosphorylates serine- and arginine-
CC       rich (SR) proteins of the spliceosomal complex and may be a constituent
CC       of a network of regulatory mechanisms that enable SR proteins to
CC       control RNA splicing. Phosphorylates SRSF1 and SRSF3. Required for the
CC       regulation of alternative splicing of MAPT/TAU. Regulates the
CC       alternative splicing of tissue factor (F3) pre-mRNA in endothelial
CC       cells. {ECO:0000269|PubMed:11170754, ECO:0000269|PubMed:19168442}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC   -!- ACTIVITY REGULATION: TG003 inhibits its kinase activity and affects the
CC       regulation of alternative splicing mediated by phosphorylation of SR
CC       proteins. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with UBL5. {ECO:0000269|PubMed:12705895,
CC       ECO:0000269|PubMed:12824502}.
CC   -!- INTERACTION:
CC       Q9HAZ1; P52294: KPNA1; NbExp=3; IntAct=EBI-633400, EBI-358383;
CC       Q9HAZ1; P60371: KRTAP10-6; NbExp=3; IntAct=EBI-633400, EBI-12012928;
CC       Q9HAZ1; P60409: KRTAP10-7; NbExp=6; IntAct=EBI-633400, EBI-10172290;
CC       Q9HAZ1; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-633400, EBI-10171774;
CC       Q9HAZ1; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-633400, EBI-10172052;
CC       Q9HAZ1; A7MD48: SRRM4; NbExp=3; IntAct=EBI-633400, EBI-3867173;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in liver, kidney, heart, muscle, brain
CC       and endothelial cells. {ECO:0000269|PubMed:11170754,
CC       ECO:0000269|PubMed:19168442}.
CC   -!- PTM: Autophosphorylates on all three types of residues.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. Lammer subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF294429; AAG10074.1; -; mRNA.
DR   CCDS; CCDS4437.1; -.
DR   RefSeq; NP_065717.1; NM_020666.2.
DR   PDB; 6FYV; X-ray; 2.46 A; A=146-480.
DR   PDBsum; 6FYV; -.
DR   AlphaFoldDB; Q9HAZ1; -.
DR   SMR; Q9HAZ1; -.
DR   BioGRID; 121501; 28.
DR   IntAct; Q9HAZ1; 28.
DR   STRING; 9606.ENSP00000316948; -.
DR   BindingDB; Q9HAZ1; -.
DR   ChEMBL; CHEMBL4203; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9HAZ1; -.
DR   GuidetoPHARMACOLOGY; 1993; -.
DR   iPTMnet; Q9HAZ1; -.
DR   PhosphoSitePlus; Q9HAZ1; -.
DR   BioMuta; CLK4; -.
DR   DMDM; 34922132; -.
DR   EPD; Q9HAZ1; -.
DR   jPOST; Q9HAZ1; -.
DR   MassIVE; Q9HAZ1; -.
DR   MaxQB; Q9HAZ1; -.
DR   PaxDb; Q9HAZ1; -.
DR   PeptideAtlas; Q9HAZ1; -.
DR   PRIDE; Q9HAZ1; -.
DR   ProteomicsDB; 81459; -.
DR   Antibodypedia; 29447; 115 antibodies from 24 providers.
DR   DNASU; 57396; -.
DR   Ensembl; ENST00000316308.9; ENSP00000316948.4; ENSG00000113240.14.
DR   GeneID; 57396; -.
DR   KEGG; hsa:57396; -.
DR   MANE-Select; ENST00000316308.9; ENSP00000316948.4; NM_020666.3; NP_065717.1.
DR   UCSC; uc003mjf.2; human.
DR   CTD; 57396; -.
DR   GeneCards; CLK4; -.
DR   HGNC; HGNC:13659; CLK4.
DR   HPA; ENSG00000113240; Low tissue specificity.
DR   MIM; 607969; gene.
DR   neXtProt; NX_Q9HAZ1; -.
DR   OpenTargets; ENSG00000113240; -.
DR   PharmGKB; PA26598; -.
DR   VEuPathDB; HostDB:ENSG00000113240; -.
DR   eggNOG; KOG0671; Eukaryota.
DR   GeneTree; ENSGT00940000160245; -.
DR   HOGENOM; CLU_000288_5_16_1; -.
DR   InParanoid; Q9HAZ1; -.
DR   OMA; SSNFRCV; -.
DR   OrthoDB; 915778at2759; -.
DR   PhylomeDB; Q9HAZ1; -.
DR   TreeFam; TF101041; -.
DR   PathwayCommons; Q9HAZ1; -.
DR   SignaLink; Q9HAZ1; -.
DR   SIGNOR; Q9HAZ1; -.
DR   BioGRID-ORCS; 57396; 10 hits in 1112 CRISPR screens.
DR   ChiTaRS; CLK4; human.
DR   GenomeRNAi; 57396; -.
DR   Pharos; Q9HAZ1; Tchem.
DR   PRO; PR:Q9HAZ1; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q9HAZ1; protein.
DR   Bgee; ENSG00000113240; Expressed in cerebellar hemisphere and 197 other tissues.
DR   ExpressionAtlas; Q9HAZ1; baseline and differential.
DR   Genevisible; Q9HAZ1; HS.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IBA:GO_Central.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0043484; P:regulation of RNA splicing; IMP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Tyrosine-protein kinase.
FT   CHAIN           1..481
FT                   /note="Dual specificity protein kinase CLK4"
FT                   /id="PRO_0000085873"
FT   DOMAIN          159..475
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..46
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          102..143
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..23
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        103..134
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        286
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         165..173
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         189
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         136
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         138
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   VARIANT         352
FT                   /note="L -> F (in dbSNP:rs35272416)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040414"
FT   VARIANT         363
FT                   /note="I -> V (in dbSNP:rs55746655)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040415"
FT   MUTAGEN         189
FT                   /note="K->R: Loss of function."
FT                   /evidence="ECO:0000269|PubMed:11170754"
FT   TURN            156..158
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          159..167
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          169..178
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           179..181
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          185..191
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           195..214
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          225..231
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          234..239
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           246..252
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   TURN            253..255
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           260..278
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   TURN            279..281
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           289..291
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          292..295
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          299..303
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          310..315
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          319..321
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           341..343
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           346..349
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           357..372
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           382..393
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           398..403
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           407..409
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   STRAND          410..415
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           422..430
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           434..437
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           443..455
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   TURN            460..462
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           466..470
FT                   /evidence="ECO:0007829|PDB:6FYV"
FT   HELIX           473..478
FT                   /evidence="ECO:0007829|PDB:6FYV"
SQ   SEQUENCE   481 AA;  57492 MW;  F402C36835CDA306 CRC64;
     MRHSKRTHCP DWDSRESWGH ESYRGSHKRK RRSHSSTQEN RHCKPHHQFK ESDCHYLEAR
     SLNERDYRDR RYVDEYRNDY CEGYVPRHYH RDIESGYRIH CSKSSVRSRR SSPKRKRNRH
     CSSHQSRSKS HRRKRSRSIE DDEEGHLICQ SGDVLRARYE IVDTLGEGAF GKVVECIDHG
     MDGMHVAVKI VKNVGRYREA ARSEIQVLEH LNSTDPNSVF RCVQMLEWFD HHGHVCIVFE
     LLGLSTYDFI KENSFLPFQI DHIRQMAYQI CQSINFLHHN KLTHTDLKPE NILFVKSDYV
     VKYNSKMKRD ERTLKNTDIK VVDFGSATYD DEHHSTLVST RHYRAPEVIL ALGWSQPCDV
     WSIGCILIEY YLGFTVFQTH DSKEHLAMME RILGPIPQHM IQKTRKRKYF HHNQLDWDEH
     SSAGRYVRRR CKPLKEFMLC HDEEHEKLFD LVRRMLEYDP TQRITLDEAL QHPFFDLLKK
     K
//
